Article successfully added.

CyFlow™ CD79b Purified

CyFlow™ CD79b Purified
Alternative Name: B29, IgB
Antibody: Yes
Antigen: CD79b
Application: Flow cytometry, Immunoprecipitation, Western blot
Clonality: monoclonal
Clone: CB3-1
Field of Interest: Immunophenotyping
Format/Fluorochrome: Purified
Isotype: IgG1
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: AC144778

For Research Use Only

$120.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
HLDA Workshop HLDA VI—WS Code CD79.1 Concentration Unit mg/mL Concentration 1... more
Close menu
CyFlow™ CD79b Purified
HLDA WorkshopHLDA VI—WS Code CD79.1
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1 mL
ImmunogenFraction of Ig-associated molecules isolated from Ramos B cells
Background InformationCD79b (IgB, B29) forms disulfide-linked heterodimer with CD79a (IgA, MB-1, MB1). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with λ5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Nakamura T, Kubagawa H, Cooper MD: Heterogeneity of immunoglobulin‑associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci USA. 1992 Sep 15; 89(18):8522‑6. < PMID: 1382292 > | Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F: CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia. 1999 Oct; 13(10):1501‑5. < PMID: 10516749 > | Rassenti LZ, Kipps TJ: Expression of Ig‑beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy‑chain allelic exclusion. Blood. 2000 Apr 15; 95(8):2725‑7. < PMID: 10753858 > | D'Arena G, Cascavilla N, Musto P, Colella Bisogno R, Pistolese G, Carotenuto M: CD79b expression in B‑cell chronic lymphocytic leukemia. Haematologica. 2000 May; 85(5):556‑7. < PMID: 10800181 > | Matutes E: New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. J Clin Pathol. 2002 Mar; 55(3):180‑3. < PMID: 11896067 > | Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG: Therapeutic potential of an anti‑CD79b antibody‑drug conjugate, anti‑CD79b‑vc‑MMAE, for the treatment of non‑Hodgkin lymphoma. Blood. 2009 Sep 24; 114(13):2721‑9. < PMID: 19633198 > | Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG: In vivo effects of targeting CD79b with antibodies and antibody‑drug conjugates. Mol Cancer Ther. 2009 Oct; 8(10):2937‑46. < PMID: 19808977 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet